Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Elocalcitol
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Adge Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Details : Adge has secured a global license to RO269228, a clinical stage oral small molecule originally developed by Roche for osteoporosis. RO269228, also known as elocalcitol, is a vitamin D analog which has demonstrated efficacy and safety in multiple Phase 2 ...
Brand Name : RO269228
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 25, 2022
Lead Product(s) : Elocalcitol
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Adge Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?